.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AE01_Fingolimod.Fingolimod

Information

Fingolimod is an oral sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and delay disability progression. It is currently widely used for this purpose.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after oral administration. Population is both sexes, ages 18-55.

References

1. David, OJ, et al., & Schmouder, RL (2012). Clinical pharmacokinetics of fingolimod. Clinical pharmacokinetics 51(1) 15–28. DOI:10.2165/11596550-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22149256

2. Wu, K, et al., & Looby, M (2012). Population pharmacokinetics of fingolimod phosphate in healthy participants. Journal of clinical pharmacology 52(7) 1054–1068. DOI:10.1177/0091270011409229 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22110161

3. Baldin, E, & Lugaresi, A (2020). Ponesimod for the treatment of relapsing multiple sclerosis. Expert opinion on pharmacotherapy 21(16) 1955–1964. DOI:10.1080/14656566.2020.1799977 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32808832

Revisions

• 06/2025 initial generated model